AZD2171
Sponsors
AstraZeneca, National Cancer Institute (NCI)
Conditions
AcuteAdvanced Breast CancerAdvanced CancerAdvanced Prostate AdenocarcinomaAdvanced Solid Metastatic TumorAdvanced Solid TumorAdvanced TumorCarcinoma
Phase 1
The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer
CompletedNCT00243347
Start: 2005-12-31End: 2009-07-31Updated: 2013-10-17
Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours
CompletedNCT00475956
Start: 2007-05-31End: 2009-10-31Updated: 2010-04-15
A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX
CompletedNCT00494221
Start: 2007-06-30End: 2012-08-31Updated: 2014-03-27
Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases
CompletedNCT00501605
Start: 2003-02-28End: 2006-02-28Target: 80Updated: 2011-01-21
Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer
CompletedNCT00502060
Start: 2004-08-31End: 2006-06-30Target: 65Updated: 2009-05-14
Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer
CompletedNCT00502164
Start: 2004-03-31Target: 40Updated: 2011-01-21
Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AML
CompletedNCT00502385
Start: 2004-04-30Target: 54Updated: 2011-01-21
A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors
CompletedNCT00502567
Start: 2005-01-31End: 2011-06-30Updated: 2011-07-27
Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic Tumors
CompletedNCT00503412
Start: 2005-11-30End: 2006-05-31Updated: 2009-01-19
A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan
CompletedNCT00503477
Start: 2005-10-31End: 2009-01-31Updated: 2009-06-12
Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer Patients
TerminatedNCT00539331
Start: 2007-09-30End: 2008-09-30Updated: 2011-06-01
Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours
CompletedNCT00621725
Start: 2008-01-31End: 2014-01-31Updated: 2014-07-15
Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients
CompletedNCT00621361
Start: 2008-02-29End: 2012-02-29Updated: 2012-12-17
Phase 2
Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours
CompletedNCT00264004
Start: 2005-11-30End: 2011-04-30Updated: 2012-08-29
Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)
CompletedNCT00278889
Start: 2006-01-31End: 2009-10-31Updated: 2012-10-24
The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).
CompletedNCT00385203
Start: 2006-09-30End: 2009-12-31Updated: 2012-07-16
AZD2171 to Treat Prostate Cancer
CompletedNCT00436956
Start: 2006-10-16End: 2014-02-05Updated: 2018-10-09
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.
CompletedNCT00454805
Start: 2007-03-31End: 2016-04-30Updated: 2016-08-03
Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
CompletedNCT00942877
Start: 2009-07-18End: 2024-12-31Updated: 2025-03-03